Saturday, September 06, 2025 10:40:46 AM
Ask yourself: Without NICE approval, how many patient will be able to afford this treatment? Will there be enough for the comoany to finally make enough $$$ to survive without dilution?
Answer is NO.
FACT. (from ~6% to ~13% survival rate for ~$200k lol)
Next question:
How long will NICE approval take? (if approved)
Answer is 2,3 maybe 4 years. (2028/29/30) FACT.
The only hope is that LP has some kind of deal with a BP.
This is why the SP is down.
These AndrewLieAravero, Dstock, TDD daily "magical" stories involving half truth with blatant lies, of "possibilities that in 10-15 years from now, this other study/combo might also have completed a ph3 study for X cancer that NWBO hold patent" ... are just ways to manipulate the dreamer/naive people into believing that this time, they will be right.
(hint-> They have never been right with any timeline, and/or SP).
You might want to pay more attention to NWBO own warning words in their 10q/k. They are not lying!!!
Answer is NO.
FACT. (from ~6% to ~13% survival rate for ~$200k lol)
Next question:
How long will NICE approval take? (if approved)
Answer is 2,3 maybe 4 years. (2028/29/30) FACT.
The only hope is that LP has some kind of deal with a BP.
This is why the SP is down.
These AndrewLieAravero, Dstock, TDD daily "magical" stories involving half truth with blatant lies, of "possibilities that in 10-15 years from now, this other study/combo might also have completed a ph3 study for X cancer that NWBO hold patent" ... are just ways to manipulate the dreamer/naive people into believing that this time, they will be right.
(hint-> They have never been right with any timeline, and/or SP).
You might want to pay more attention to NWBO own warning words in their 10q/k. They are not lying!!!
Recent NWBO News
- How Advanced Drug Delivery Could Improve Existing Cancer Treatments • GlobeNewswire Inc. • 06/01/2026 12:30:00 PM
- CNS Drug Delivery Breakthroughs Unlock Significant Biotech Market Opportunities • InvestorsHub NewsWire • 05/11/2026 01:00:00 PM
- CNS Drug Delivery Breakthroughs Unlock Significant Biotech Market Opportunities • GlobeNewswire Inc. • 05/11/2026 12:30:00 PM
- Northwest Biotherapeutics Appoints Dr. Annalisa Jenkins As Strategic Adviser To Advance Dendritic Cell Cancer Vaccine Platform • PR Newswire (US) • 04/30/2026 04:38:00 PM
- Northwest Biotherapeutics Appoints Dr. Annalisa Jenkins As Strategic Adviser To Advance Dendritic Cell Cancer Vaccine Platform • PR Newswire (US) • 04/30/2026 04:30:00 PM
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 04/21/2026 04:15:08 AM
- Form POS AM - Post-Effective amendments for registration statement • Edgar (US Regulatory) • 04/16/2026 09:25:30 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/07/2026 04:30:50 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/31/2026 09:04:37 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/15/2026 10:06:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/02/2026 10:14:59 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 11/28/2025 09:43:27 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/25/2025 10:23:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/20/2025 09:26:03 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 11/19/2025 09:15:48 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 09:44:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/31/2025 04:29:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2025 08:40:05 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/24/2025 04:28:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/14/2025 06:22:26 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2025 09:00:38 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 07/01/2025 09:04:38 PM
